←
avidresearch34,678 posts
avidresearch avatar

avidresearch

@avidresearch
◷ Joined October 2009▧ 1,631 Photos and videos
avidresearch avatar
avidresearch@avidresearch·16h

Ok.. that’s confidence.

SHE RAISED GUIDANCE FOR NEXT YEAR. Colette just dunked on the Nvidia bears from the foul line. "We are raising our fiscal year 2028 outlook. We expect revenue to grow approximately 75% year over year, up from 70%, and off what is now a higher fiscal 2027 base" $NVDA

avidresearch avatar
avidresearch@avidresearch·Nov 17

Interesting they at least got a review for MF despite failing on symptoms, something that pelabraisb was not granted. Pelabrsib biggest concern was increased transformation to AML

$KPTIQ Karyopharm FDA Accepts sNDA for XPOVIO (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis PDUFA 06/28/27

GreenMtnTrader avatar
⟳ avidresearch retweeted
GreenMtnTrader@vtcarguy81·Nov 16

“VK2735's retatrutide-like efficacy, tirzepatide-like tolerability, and convenience advantages puts it in a competitive position ahead of 2H27 Ph3 VANQUISH readout."

$VKTX ... Viking Therapeutics: ObesityWeek Supports Best-in-Class Potential -- Oppenheimer (29.22) Analyst Jay Olson commented, "We're encouraged by VK2735's best-in-class potential following VKTX's ObesityWeek event, where 3 leading KOLs identified treatment discontinuation and resulting weight regain as the greatest unmet needs in obesity. VK2735 could uniquely address both through every-other-week and monthly subQ maintenance dosing plus an oral option, which neither tirzepatide nor retatrutide offers. We highlight: 1) maintenance data showing up to 97% weight-loss retention with placebo-like GI tolerability; 2) ~22% weight loss at week 33 with the Ph3 17.5mg dose and no apparent plateau; 3) sustained lipid improvements; 4) a VENTURE analysis showing 74% of patients improved =1 BMI category; and 5) VK3019 primate data supporting amylin combinations. VK2735's retatrutide-like efficacy, tirzepatide-like tolerability, and convenience advantages puts it in a competitive position ahead of 2H27 Ph3 VANQUISH readout."

Rotten Tomatoes 🍅 avatar
⟳ avidresearch retweeted
Rotten Tomatoes 🍅@RottenTomatoes·Nov 16

Robert Pattinson has officially been cast as James Bond. Watch the first teaser for the new 007.

0:26
avidresearch avatar
avidresearch@avidresearch·Nov 16

$HELP no idea why market is punishing such great data. Suicidal ideation/attempts were seen in $JNJ Spravato clinical program. It’s annualizing at $2.5B/yr. Efficacy is best in class.

Post attachment
avidresearch avatar
avidresearch@avidresearch·Nov 16

Also $help placebo arm acted more in line with other MDD trials compared to $DFTX ph3 which had a very low placebo change at week 6 (think close to 5). Clean efficacy and strongest from a phase 3 study in MDD.

$HELP change from baseline at week 6 of 19.5 for the active arm is highest ever in a phase 3 trial for MDD (across mono and adjunctive setting) Price action is 😴

Post attachment
avidresearch avatar
avidresearch@avidresearch·Nov 16

$HELP change from baseline at week 6 of 19.5 for the active arm is highest ever in a phase 3 trial for MDD (across mono and adjunctive setting) Price action is 😴

Post attachment
avidresearch avatar
avidresearch@avidresearch·Nov 16

$HELP very plausible explanation for the one relevant SAE. If focus shifts to efficacy, it’s the best in any adjunctive setting. $20 would still value this well below $DFTX

avidresearch avatar
avidresearch@avidresearch·Nov 16

Damn!! Large delta. $HELP

$HELP Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in MDD -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the MADRS (p< 0.0001)